Literature DB >> 15940472

Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats.

Sherif Y Saad1, Tawfeeg A O Najjar.   

Abstract

The aim of this study was to analyze the effect of streptozotocin (STZ)-induced diabetic state and the insulin-like acting, vanadyl sulphate (VS) on cyclosporine A (CyA) related nephrotoxicity in rats. Male Wistar rats were divided into six groups, of 12 animals each: The control, diabetic rats and diabetic rats whose drinking VS in the drinking water in a concentration of 1 mg/ml. Another three similarly treated groups were injected intra-peritoneally (ip) with CyA in a dose of 25 mg/kg/day for ten doses, 10 days after diabetic induction by using a single dose of STZ of 65 mg/kg. Rats were sacrificed 48 h after the last CyA dose and serum as well as kidneys were isolated and analyzed. Treatment with CyA to control normoglycemic rats resulted in significant increases in kidney weight, serum creatinine, urea nitrogen, cholesterol and triglycerides (TG) levels. Also, the kidney tissue of CyA-treated control animals showed significant increases in total nitrate/nitrite (NO(x)) concentration and malondialdehyde (MDA) production level as well as depletion of glutathione (GSH) content and glutathione peroxidase (GSH-P(x)) activity level. Histopathologic evaluation of CyA-treated control rats revealed tubular atrophy, hyaline casts and focal tubular necrosis. However, treatment of diabetic rats with CyA showed significant reduction in serum creatinine and elevation in TG level as well as reductions in the kidney NO(x) concentration and MDA production level and increase in GSH concentration compared to CyA-treated control rats. Moreover, histopathology of the kidney of CyA-treated diabetics showed typical changes of the diabetic controls revealing glomerular hypertrophy and tubular dilation. On the other hand, treatment with CyA to those diabetic animals administered VS in the drinking water resulted in exacerbation of renal dysfunction, manifested by significant increases in serum indices of nephrotoxicity, cholesterol, TG and bilirubin levels. Also, VS administration to CyA-treated diabetics showed significant increase in kidney NO(x) concentration compared to those CyA-treated diabetics drinking plain tap water, and to a level significantly lower than those CyA-treated controls. Histopathologically, kidney of CyA/VS-treated diabetic showed marked CyA related changes. In conclusion, STZ-induced diabetes might provide partial protection against CyA-induced renal dysfunction. Also, treatment of hyperglycemia with VS might exacerbate CyA related nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940472     DOI: 10.1007/s00204-005-0663-7

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Possible protective effect of the algae spirulina against nephrotoxicity induced by cyclosporine A and/or gamma radiation in rats.

Authors:  Maha M Aziz; Nihad I Eid; Ahmed S Nada; Nour El-Din Amin; Afaf A Ain-Shoka
Journal:  Environ Sci Pollut Res Int       Date:  2018-01-15       Impact factor: 4.223

2.  In vivo toxicity evaluation of two polyoxotungstates with potential antidiabetic activity using Wistar rats as a model system.

Authors:  Marko Dinčić; Mirjana B Čolović; Marija Sarić Matutinović; Mila Ćetković; Tamara Kravić Stevović; Ali S Mougharbel; Jasna Todorović; Svetlana Ignjatović; Branimir Radosavljević; Milan Milisavljević; Ulrich Kortz; Danijela Z Krstić
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 3.361

3.  Influence of overt diabetes mellitus on cyclosporine pharmacokinetics in a canine model.

Authors:  Khalid M Alkharfy
Journal:  Exp Diabetes Res       Date:  2009-10-20

4.  Effect of aerobic exercise against vanadyl sulphate-induced nephrotoxicity and hepatotoxicity in rats.

Authors:  Fatemeh Ahmadi; Mehdi Nematbakhsh; Mehdi Kargarfard; Fatemeh Eshraghi-Jazi; Ardeshir Talebi; Soheila Shirdavani
Journal:  J Renal Inj Prev       Date:  2016-08-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.